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A model of the human genetic disorder, Gaucher disease, can be rapidly generated in mice by the 
injection of emulsified glucosylceramide and an inhibitor of the lipid's hydrolase, conduritol B 
epoxide. The liver grows rapidly as it absorbs the load of lipid but the effect disappears as new 
glucosidase is formed and the load is hydrolyzed. This normalization process is accelerated by 
treatment with phosphatidylserine, which is a known stimulator of the enzyme. It is possible that 
injecting the phospholipid into Gaucher patients would have a therapeutic effect since it might help 
them utilize their residual glucosidase to destroy stored glycolipid. ® 1988 ~caaem±o Press, ~n~. 
The enzyme that is defective in Gaucher disease, glucosylceramide ]3-glucosidase (E.C.3.2.1.45), is 
activated by two materials acting in concert, a stimulating protein and an acidic lipid, such as 
phosphatidylserine. Not only does PS act on the normal enzyme, it also acts on the defective enzyme in 
cultured fibroblasts (1,2). In a study of neuroblastoma cells that were loaded with GlcCer in culture, the 
addition of PS to the medium considerably speeded the hydrolysis and disappearance of the GlcCer 
(3). This finding may mean that the glucosidase is normally not in a fully activated state and the 
possibility therefore exists that the defective enzyme of Gaucher patients is also not in a fully 
activated state. Injected phosphatidylserine has been found to enter tissues of intact animals (4) 
without exerting any harmful effects. If PS could be made to reach the tissues of the patients at a 
sufficient level it might have therapeutic value. 
We have recently shown that a model form of Gaucher disease could be produced in one day in mice 
by injecting them with an emulsion of GlcCer (5). The relatively heavy load of glycolipid was rapidly 
taken up by the liver, producing the accumulation of GlcCer and glucosidase activating protein, and the 
organ enlargement so typical of the disorder. As noted before, the enlargement could not be attributed to 
edema but represented actual increase in organ mass. The phenomenon was accentuated by also injecting 
an inactivating inhibitor of glucosidase, conduritol B epoxide, which evidently protected the loaded 
lipid against hydrolysis for a while. These observations made it possible to test the "Gaucher" mice to 
see whether exogenous PS could accelerate the disappearance of the stored lipid. 
MATERIALS AND ]~fETHODS 
Materials. GlcCer and CBE were prepared here (6,7), PS was from bovine brain (Sigma Chemical). The 
GlcCer was emulsified with 3/4 its weight of Myrj 52 (ICI America Inc.) in isotonic saline prior to 
Abbreviations: GlcCer, glucosylceramide; PS, phosphatidylserine; CBE, conduritol B epoxide. 
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injection at a dosage of 250 mg/kg. The PS was emulsified similarly with 1/3 its weight of detergent. 
The mice (16 day old males, strain Hsd CF1, Harlan Industries) were sorted with a computer program 
into weight-matched groups of three or five, having similar mean weights and weight standard 
deviations (8). Two or three groups, in separate cages with separate mothers, were used for each 
experimental test (a total of 10 or 9 mice). 
Methods. The various compounds were injected i.p. and the mice were killed by cervical dislocation. 
The livers were washed with cold saline, wiped dry, frozen in pentane cooled with dry ice, and 
weighed individually. They were stored at -65°C, pooled in groups of three or five, then homogenized 
in water. Duplicate aliquots were taken for protein and DNA determination and glucosidase assay 
with [3H]GlcCer as substrate (5). Thus the assays yielded four or six values per experimental point. 
Thin-layer chromatography of the liver GlcCer was quantitated by video/computer charring 
densitometry (9). Total lipids were determined gravimetrically with a hexane-isopropyl alcohol 
extract. It should be noted that the assay system for the enzyme included taurocholic acid (3), which 
activates glucosidase independently of endogenous activators. 
RESULTS 
Changes in Liver Due to GlcCer__Initially we tested the mice with a single injection of GlcCer 
emulsion, without CBE, to see how long the changes in liver persisted (Table 1). As observed before (5), 
there were striking increases in liver size, total DNA, total protein, and specific activity of 
glucosidase. At every time point, the glucosidase activity was significantly higher in the lipid- 
injected mice, compared with the controls, with a maximum increase of 42% by 2 days. Even after 7 days 
there was still a significant increase, although it was only 7%. 
While previous experiments had yielded a distinct increase in liver weight within 1 day, here it 
took 2 days to reach a large effect (33% increase). The growth stimulation disappeared during the next 
2 days. (The controls show increases with time due to normal mouse growth.) The total DNA in each 
liver behaved similarly, reaching a value 22% above the control weights (p<0.05, Student t-test). The 
total protein values were significantly higher (10%, p<0.005) by 1 day and 29% higher (p<0.005) by 2 
days. Here too the effect disappeared during the next 2 days. The GlcCer contents, evaluated by visual 
examination of thin-layer plates, were markedly higher in all lipid-injected mice. 
In a similar experiment, in which the mice were injected with three times the usual GlcCer dose and 
examined only 1, 2, and 4 days afterward, thin-layer chromatography of the lipids from 0.25 mg of 
liver showed that the normal liver did not contain detectable GlcCer but that the livers from GlcCer- 
injected mice revealed distinct spots. The maximal concentration of glycolipid was attained 2 days 
Table 1 
Effect of a single injection of glucocerebroside (emulsified in Myrj 52/saline) followed over time. Control 
mice were injected with saline only. 
Group Liver weight DNA weight Protein weight Glucosidase 
(rag) (rag/liver) (rag~liver) ( nmoll hrlmg )* 
1-day Controls 303 + 39 1.07 + .03 40.9 + 1.1 4.34 + .07 
1-day GlcCer 316 + 34 1.03 + .05 45.0 + 1.2 4.90 +_ .19 
2-day Controls 321 _+ 27 1.22 + .04 44.8 + 2.9 4.15 + .18 
2-day GlcCer 426 + 40 1.49 + .16 57.8 + 4.4 5.91 + .42 
4-day Controls 465 + 55 1.65 + .11 64.8 + 1.3 4.30 + .05 
4-day GlcCer 436 + 77 1.63 + .31 61.6 + 11.5 4.76 + .11 
7-day Controls 618 + 92 2.22 + .15 84.9 + 4.1 4.24 + .03 
7-day GlcCer 584 _+ 100 2.16 + .06 82.2 + 1.2 4.53 + .08 
*Enzyme activity based on liver weight. 
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after the injection. It is interesting that the 4-day livers, as in the other experiment, had normal 
weights and DNA contents yet contained about 2/3 the maximal GlcCer seen at 2 days. 
Effect on Liver of GlcCer vlus CBE--Since the endogenous glucosidase activity was so high after 
GlcCer injection, and since so much GlcCer disappeared quickly, we tried to prolong the period of high 
lipid concentration by inactivating the enzyme with CBE (80 mg/kg),  injected with the glycolipid. Six 
groups of nine mice each were used. One group was injected with saline and all the remaining groups 
were injected with GlcCer/CBE. The saline controls and one of the lipid-loaded groups were killed 24 
hr later (Group A, Fig. 1). At that point, groups B and C mice were injected with saline or 20 mg/kg  of PS 
and Group B was killed 1 day later. Group C mice received a second saline or PS injection at that point 
and were killed 1 day later. 
As seen before, the GlcCer/CBE injection produced rapid liver growth in 24 hr: a 28% increase (Group 
A, Fig. 1). By 2 days (left bar of Group B), the liver weights were even higher (35%); by 3 days they 
were 44% higher (left bar of Group C). These changes were significant at the p<0.005 level. Little of 
this growth can be attributed to normal animal growth since these GlcCer/CBE animals did not show 
significant differences in body weight. Thus it would appear that the CBE acted to prolong the liver 
growth phenomenon by prolonging the storage of GlcCer. 
Effect of P S  o n  Liver Size--When the GlcCer-loaded mice were injected with PS, there was a partial 
return to normal liver weights (right bar of Group B, Fig. 1). The decrease was 13%, p<0.01, compared 
with the untreated mice (left bar of Group B). However there was also a significant decrease in body 
weight too (12%) so the PS effect might have involved the entire body. In the case of mice injected with 
PS on two successive days, the livers were 10% lighter (p<0.01%, Group C). In this case there was a 
negligible difference in body weight so the effect seems to have been specifically on the liver. 
L i v i d  Chan~es--Measurement of the total liver lipids (Group A, Fig. 2) showed that GlcCer loading 
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Fig. 1. Changes in liver weight following a single injection of GlcCer, 250 mg/kg, and CBE, 80 mg/kg, 
into each mouse. Each bar is based on the data from three groups of three mice each. The animals of 
Group A were killed 1 day after the lipid (or saline) injection; the animals of Groups B and C were 
killed 2 and 3 days after the initial cerebroside injection. The mice represented by the right bars 
received one or two injections of phosphatidylserine (20 mg/kg) after the glycolipid injection. The error 
bars indicate one standard deviation, based on nine liver weights. 
Fig. 2. Changes in mouse liver total lipids following a single injection of GlcCer (same experiment as in 
Fig. 1). The error bars show the S.D. calculated from the six values obtained from the three subgroup of 
three mice each. 
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the next 2 days. (left bars of Groups B and C). One day of treatment with PS produced significant 
lowering (23%, comparing the two bars of Group B); 2 days of PS treatment lowered the lipids 16% 
(Group C). These are the effects to be expected if PS reached the liver and accelerated the hydrolysis 
of the stored GlcCer. 
Glucosidase Changes--Measurement of the liver glucosidase activities showed the expected initial 
decrease in active enzyme due to reaction with CBE (Group A, Fig. 3). As observed before (5), the 
presence of exogenous GlcCer seems to partially protect the enzyme against the inhibitor and to induce 
much faster synthesis of the enzyme than one sees with CBE alone (10). As the liver synthesized new 
glucosidase molecules during the next 1 and 2 days the enzyme level came closer to normal although it 
was still not significantly recovered (compare the left bars of all three groups). 
Injection of PS, once or twice, acted to increase the glucosidase activity and bring it closer to normal. 
The increase was 10% above the controls after a single PS injection (compare the two bars of Group B, 
p<0.01); after two injections the increase was 20% (compare the two bars of Group C, p<0.01). 
G!~cocerebroside Changes--Determination of the liver GlcCer from the same animals showed the 
expected heavy uptake of the lipid (Group A, Fig. 4). The content remained steady over the next 2 days 
(left bars of all three groups). PS injection had a large effect on the rate of GlcCer disappearance. The 
single injection led to a 58% decrease in total amount per mouse (compare the two bars of Group B), and 
two PS injections led to a 69% decrease (Group C). 
Control Exveriment--To determine whether the effect of PS on glucosidase was the result of direct 
reduction in the amount or activity of the enzyme, rather than to the assumed mechanism (acceleration 
of the normal hydrolysis of stored GlcCer), we injected groups of nine normal mice at time zero with 
saline or PS emulsified with Myrj (Table 2). One day later the injections were repeated and the mice 
were killed 5 hr later. Three dosages of PS were used: 10, 20, and 50 mg/kg body weight. The PS-treated 
mice showed no significant change in body weight (6.2 g aver.), liver weight (213 mg aver.), or liver 
lipid concentration (65 mg/g). The glucosidase specific activities showed negligible but significant 
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Fig. 3. Changes in G|cCer glucosidase specific activity in livers of mice injected with G]cCer/CBE 
and/or 1-~ (same e×periment as in Fig. 1). The error bars indicate the standard deviation calculated 
from the six assay values obtained. 
Fi~. 4. Changes in total l iver GlcCer content (p.g/liver) from the mice described in Fig. 1. 
158 
Vol. 152, No. 1, 1988 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
Table 2 
Effect of phosphatidylserine injection into normal 16-day old mice. The mice were injected with either 
saline or a PS emulsion in Myrj/saline, then reinjected with the same dose 24 hr later and killed after 5 
hr. The values shown are means and standard deviations, 
Dose Body weight Liver weight Glucosidase activity 
(rag/kg) (g) (rag) (,mollhr/mg) 
0 6.13 + 0.33 207+ 20 3.35 + 0.08 
10 6.35 + 0.38 217+ 25 3.32 + 0.06 
20 6.18 + 0.34 210+ 22 3.26 + 0.05 
50 6.30 + 0.35 220+ 25 3.22 + 0.04 
normal, unloaded mice has only a minor effect on GlcCer metabolism and liver size, and that it does not 
induce an elevated glucosidase activity. 
DISCUSSION 
An interesting observation was made in the time studies (without IS), namely the return to normal 
liver size despite the continued presence of an elevated level of GlcCer. This may be the result of 
gradual confinement of the stored lipid to a non-stimulatory location in liver cells, A study in rats of 
the tissue distribution of injected L-GlcCer (the inert isomer of the natural glycolipid) showed that 
much of the material ended up in liver cells (11). Release from Kupffer cells (which store most of the 
GlcCer in Gaucher disease) was slow when compared to other liver cells. If the natural enantiomer used 
in our experiments behaved similarly, one could attribute the growth stimulation phenomenon to 
uptake by hepatocytes. 
The pharmacology of PS is still little known so alternative explanations of its effects on liver size, 
GlcCer levels, total lipids, and 13-glucosidase might be offered. Phosphatidylserine can enter the 
organs of intact animals (4) and affect brain levels of glucose and neurotransmitters (12-14). Effects on 
prolactin secretion and turnover of phosphatidylinositol were observed (15). Improvement in learning 
by rats was reported (16). Some of the observed changes have been attributed to conversion of PS to 
lysoPS. The empirical observation that we report here, of relevance to Gaucher therapy, is that a PS 
emulsion can help to get rid of stored GlcCer. 
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